Berberine enhances the sensitivity of radiotherapy in ovarian cancer cell line (SKOV-3)

• Published in: Saudi pharmaceutical journal 2023-01, Vol.31 (1), p.110-118
• Main Authors: Aleissa, Mohammed S., AL-Zharani, Mohammed, Alneghery, Lina M., Aleissa, Abdulmalik M.
• Format: Article
• Language: English
• Subjects: Berberine; Cancer; Original; Ovarian; Radiotherapy; SKOV-3
• ISSN: 1319-0164; 2213-7475
• DOI: 10.1016/j.jsps.2022.11.009

Berberine, a well-known isoquinoline alkaloid derivative, has a varied range of pharmacological effects. Herein, we notice the radio-modulatory outcome of berberine in cultured ovarian cancer (SKOV-3) cells exposed to γ-rays as radiotherapy (RT). Cells pre-treated with berberine were irradiated by γ-irradiation and the liberation of reactive oxygen species (ROS) was analyzed by flow cytometry. Apoptotic cell death along with the DNA damage associated with protein expressions was projected by flow cytometry and confocal microscopy. Experimental findings established that berberine might be a capable radiosensitizer for treating SKOV-3, because of oxidative DNA damage. Moreover, the in-silico study of the compound, berberine suggests free energy of binding (ΔG) −7.5 kcal/mol with SKOV-3 and −8.8 kcal/mol of PALB/BRCA2, which proves an effective and compact binding of the complex and is safe for future clinical trials. Thus, our approach is probably to widen the field of study of SKOV-3 and PALB/BRCA2 from the inhibition of these targets as a prospective nutraceutical for the anti-cancer theragnostic candidate.